United States

Sirona Biochem Corp (SBM.V)

SBM.V on TSX Venture Exchange

3:58pm EDT
Change (% chg)

$0.00 (+0.00%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Sirona Biochem says Wanbang Biopharma will formulate product in Jan 2017 to prepare for clinical trial
Thursday, 8 Dec 2016 08:00am EST 

Sirona Biochem Corp : Sirona Biochem Corp - "expect to receive one or more term sheets from interested parties before end of Q4 2016" for licensing agreement for TFC-1067 . Sirona Biochem Corp - Wanbang Biopharmaceuticals will formulate product (SGLT2 inhibitor) in January 2017 to prepare for a clinical trial . Sirona Biochem - Wanbang Biopharma will conduct additional pharmacology, toxicology study and file IND package with Chinese FDA for SGLT2 inhibitor .Sirona Biochem Corp - Valeant is aware of delays in scale-up and has not altered plans to commercialize skin lightener, TFC-849.  Full Article

More From Around the Web

BRIEF-Sirona Biochem announces management changes

* Sirona Biochem announces management changes Source text for Eikon: Further company coverage: